About Bernie Tobin
Bernie Tobin is an independent member of the board of directors at Inmedix, which runs a bloodless, cloud-based diagnostics platform for autoimmune disease. Inmedix announced on July 15, 2020 that it had appointed him to its board.
Tobin has worked in healthcare for 25 years. His most recent role was president of Crescendo Bioscience, a Myriad Genetics subsidiary that used proteomics to serve patients with autoimmune disorders. Earlier he held senior positions at Amgen, including general manager of the Netherlands and Brazil and global head of commercial excellence. He also held leadership roles in the commercial organization at Eli Lilly and Co. He has a B.S. in public service and administration from Iowa State University and an MBA from Duke University's Fuqua School of Business.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Bernie Tobin in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Bernie Tobin works with at each company, as listed on that company's latest Form D.